From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America

Ann Hepatol. 2023 Nov 30:101185. doi: 10.1016/j.aohep.2023.101185. Online ahead of print.ABSTRACTThe most common primary liver tumors are hepatocellular carcinoma and cholangiocarcinoma. They constitute the sixth most common neoplasia and the third cause of cancer-related deaths worldwide. Although both tumors may share etiologic factors, diagnosis, prognostic factors, and treatments, they differ substantially in determining distinctive clinical management. In recent years, significant advances have been made in the management of these neoplasms, particularly in advanced stages. In this review, we focus on the most relevant diagnostic, prognostic, and treatment aspects of both, hepatocellular carcinoma and cholangiocarcinoma, underlying their applicability in Latin America.PMID:38042481 | DOI:10.1016/j.aohep.2023.101185
Source: Annals of Hepatology - Category: Gastroenterology Authors: Source Type: research